Rare Disease Therapeutics, Inc. (RDT)
BiotechRare Disease Therapeutics, Inc. (RDT) is a biotechnology company focused on Immunology, Dermatology. Key products include Anascorp.
Rare Disease Therapeutics, Inc. (RDT)'s Key Drugs
Rare Disease Therapeutics, Inc. (RDT)'s core commercial portfolio centers on Anascorp, Anavip, spanning Immunology and Dermatology — its most strategically important drugs approved in the last 15 years.
Rare Disease Therapeutics, Inc. (RDT)'s Recent FDA Approvals
New NDA/BLA approvals for Rare Disease Therapeutics, Inc. (RDT) over the last two years — novel drugs only, excluding generics and label supplements.
Rare Disease Therapeutics, Inc. (RDT)'s Therapeutic Areas
Rare Disease Therapeutics, Inc. (RDT)'s approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology, across 2 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Rare Disease Therapeutics, Inc. (RDT)'s Top Competitors
Rare Disease Therapeutics, Inc. (RDT)'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Rare Disease Therapeutics, Inc. (RDT) Pipeline Snapshot
Rare Disease Therapeutics, Inc. (RDT) has 15 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 8 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Anascorp leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling